HOME >> MEDICINE >> NEWS
Old Drugs, New Tricks

In recent years two Scandinavian studies have shown that fibrates (lipid-lowering drugs) reduce atheroma plaque formation , through an unknown mechanism. Bart Staels and Professor Jean-Charles Fruchart (INSERM 325, Lille 2 University and Lille Pasteur Institute), in collaboration with the teams headed by Jacques Maclouf (INSERM 348, directed by Sylviane Levy-Toledano) and Alain Tedgui (INSERM 141, directed by Bernard Levy), have now discovered why : fibrates have an anti-inflammatory effect on vessel walls.

Fibrates, a class of drugs that reduce blood fat levels, have been used for about a decade in the treatment of some forms of hyperlipidemia and atherosclerosis. Fibrates bind to PPARa, a receptor present in the liver and involved in fatty acid breakdown . PPARa acts as a messenger, allowing the body to adapt to its nutritional environment (especially ingestion of large amounts of fat). Fibrates, synthetic compounds that bind to this receptor, stimulate PPARa activity and thereby reinforce its lipid-lowering action.

The INSERM researchers showed that PPARa receptors are also present in vascular muscle cells, which participate in the formation of atheroma plaque and restenosis after angioplasty . These vascular PPARa receptors were found to inhibit the inflammatory response of the vascular wall which leads to atheroma plaque formation (see inset). Fibrates, by activating PPARa, inhibit the production of inflammatory cytokines such as interleukin-6 (IL-6) and prostaglandin by vascular muscle cells in vitro. They also inhibit the induction of an enzyme called Cox-2 (cyclooxygenase), which serves as a marker of vascular cell inflammation.

The mechanism of action of these PPARa receptors in the vascular wall was also elucidated. The receptors exert at least part of their anti-inflammatory effect by interfering with a signaling pathway called NFkB, which is also activated during inflammatory cytokine production. PPARa inhibits the inflammatory response by
'"/>

Contact: Jean-Charles Fruchart
Jean.Charles.Fruchart@pasteur-lille.fr
33 3 20 87 73 52
French National Institute for Health and Medical Research (INSERM)
24-Jun-1998


Page: 1 2 3

Related medicine news :

1. Even in an era of HAART Drugs, HIV patients are vulnerable to opportunistic infections

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder of ... ElderCounsel, a national organization of elder law and special needs planning attorneys. “Membership in ... It also provides a forum to network with elder law attorneys nationwide,” said Somekh. ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading ... to advocate for action towards gender equality at their inaugural Summit in New York ... globe, and reached a social audience of over 3 million. To watch the Mobilize ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... and Agile Software Development, has been awarded a contract by the Center for ... Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in a ...
(Date:10/12/2017)... CA (PRWEB) , ... October 12, 2017 , ... ... Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent technology. ... a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can ...
(Date:10/12/2017)... ... ... The American College of Medical Informatics (ACMI) will present the 2017 Morris ... of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is taking ... in the field of medical informatics, this prestigious award is presented to an individual ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... , Oct. 10, 2017   West Pharmaceutical ... innovative solutions for injectable drug administration, today shared the ... ID Adapter for improving the intradermal administration of polio ... Skin Vaccination Summit in May 2017 by Dr. ... Polio Department, World Health Organization (WHO), and recently published ...
(Date:10/4/2017)... Oct. 4, 2017  South Korean-based healthcare product Development ... aide "cprCUBE" on Kickstarter. The device will educate the ... arrests with better efficiency compared to the dated and ... feedback on efficacy of the compression for a more ... a goal to raise $5,000. ...
(Date:10/2/2017)... Diplomat Pharmacy, Inc. (NYSE: DPLO ... LLC , and named its founder as Diplomat,s chief ... Tennessee , will operate under Diplomat subsidiary ... offerings for health care partners to include IT outsourcing, ... "In an interoperable world, technology delivers comprehensive insight ...
Breaking Medicine Technology:
Cached News: